Transplant Ineligible Multiple Myeloma: Updates to the MAIA Study

Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.